ipragliflozin
Sign in to saveAlso known as C21H21FO5S
Ipragliflozin (INN, trade names Suglat) is a pharmaceutical drug for treatment of type 2 diabetes. Ipragliflozin, jointly developed by Astellas Pharma and Kotobuki Pharmaceutical, was approved in Japan on January 17, 2014, and in Russia on May 22, 2019.
In the Vinony graph
Within Vinony's link graph, ipragliflozin is referenced by 152 other articles, and connects out to metformin, alogliptin and anti-diabetic medication.
It is catalogued under topics including Benzothiophenes, Drugs with non-standard legal status and Fluoroarenes.
Its subject is documented across 5 Wikipedia language editions.
Wikidata facts
- Mass
- 404.109
Show 4 more facts
- chemical formula
- C₂₁H₂₁FO₅S
- isomeric SMILES
- C1=CC=C2C(=C1)C=C(S2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)F
- Commons category
- Ipragliflozin
- canonical SMILES
- C1=CC=C2C(=C1)C=C(S2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)F
Sources (2)
via Wikidata · CC0
~6 min read
Encyclopedic overview
5 sectionsContents
- Clinical trials
- Commercialization
- Marketing
- Intellectual Property
- References
{{Infobox drug | drug_name = | IUPAC_name = (2S,3R,4R,5S,6R)-2-{3-[(1-benzothiophen-2-yl)methyl]-4-fluorophenyl}-6-(hydroxymethyl)oxane-3,4,5-triol | image = Ipragliflozin structure.svg | image_class = skin-invert-image | width = 275 | image2 = Haworth projection of ipragliflozin.svg | image_class2 = skin-invert-image | width2 = 225 | caption = Haworth projection (bottom)
| tradename = Suglat | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_AU_comment = | legal_CA = | legal_NZ = | legal_UK = | legal_US_comment = Not available | legal_UN = | legal_status = Rx-only (JP) | routes_of_administration = By mouth (tablets)
Excerpted from Wikipedia’s “ipragliflozin” article, available under the CC BY-SA 4.0 licence.